Changing consumer lifestyles and evolving tastes to help the liquor maker’s growth
ASPHL is adding inventory at a healthy pace and has a strong balance sheet with zero net debt
India’s largest organised eyewear retailer has built a compelling omni-channel model and is well-positioned to benefit from market formalisation
Stable tax regime, consumption boost, easing cost pressure to aid growth, profitability
Given the strong tailwinds in the MF industry, the stock could be a long-term compounder
Sector-specific headwinds in airlines and railways as well as one-time ESOP charges impacted quarterly numbers
The company is entering a new phase, expanding and consolidating its technology-led ventures to complement its established strengths in engineering, construction, manufacturing, and project management.
Decent performance in a seasonally weak quarter, but most importantly, the alcohol beverage foray will be a key pivot
Strong distribution network, push for premium products support expansion plans
Foray into allied segments likely to support growth, going forward
With a strong pipeline of projects, the company is investing in a new shipyard to expand capacities
Outperformance of Indian equities on the cards, but USD/INR may remain rangebound
Robust deal wins, strong execution, continued operational efficiencies and investment in AI are positives
The packaged food industry is poised for healthy growth, and, with a strong balance sheet and cash generation, OIL is well placed to accelerate growth.
While agrochemicals pose challenges due to the imports from China, order deferment, and US tariffs, off-take for new agro products, along with better realisations for refrigerants, should be helpful
Valuation re-rating hinges on cyclical recovery in the core segment
Robust quarterly performance sets the stage for continued growth in H2
Strong business fundamentals and visibility of earnings growth justify the rich valuation
Growth rebound story at a reasonable valuation
Earnings are expected to taper off in the medium term due to intensifying market competition
The company plans to launch the injectable version of Semaglutide in a number of countries, starting with Canada in January 2026. India and Brazil will follow
Q2 shows modest improvement in operations while profitability and segmental performance remain variable
With the economy looking up, the bank seems ready to ride the upcycle
The company’s strong rebound in the FMEG business and outperformance in W&C continue
The government's move to cut GST on cement is a major uplift for infrastructure and real estate sectors. It will lower construction costs, generating strong demand for both new and existing projects